Amgen Raises Outlook After 3Q Profit, Sales Rise

What happened

Amgen raised its yearly outlook after third-quarter profit and sales rose. It now expects revenue of $38.9 billion to $39.7 billion and adjusted earnings per share of $22.90 to $23.70, both above prior guidance.

Confirmed

Global impact / market context

Higher guidance signals Amgen expects more cash coming in from product sales, driven by volume growth. That can support spending on research and business needs, and may reassure investors who value steady profit and rising revenue.

Analyst inference

Third-quarter revenue and adjusted earnings beat analyst forecasts, while product sales rose 8% on volume. Repatha and Evenity led growth, but new biosimilar competition cut sales of Prolia and Xgeva, showing mixed performance across the drug portfolio.

Analyst inference

What to watch

1. Watch whether full-year revenue lands within the raised $38.9 billion to $39.7 billion range and adjusted earnings per share within $22.90 to $23.70, as Amgen now projects. Confirmed
2. Track Repatha and Evenity sales growth, since these treatments drove recent gains; slower growth would reduce the revenue momentum behind the raised outlook. Analyst inference
3. Monitor biosimilar pressure on Prolia and Xgeva, because continued volume losses in these bone-health drugs could offset growth elsewhere and weigh on overall product sales. Analyst inference

Evidence

• Original source link unavailable